BidaskClub upgraded shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a strong-buy rating in a report published on Friday.
Several other brokerages also recently issued reports on KURA. Zacks Investment Research downgraded shares of Kura Oncology from a hold rating to a sell rating in a research report on Tuesday, January 8th. Piper Jaffray Companies set a $25.00 price objective on shares of Kura Oncology and gave the company a buy rating in a research note on Monday, December 3rd. HC Wainwright reissued a buy rating and issued a $31.00 price objective on shares of Kura Oncology in a research note on Monday, December 3rd. Oppenheimer set a $32.00 target price on shares of Kura Oncology and gave the stock a buy rating in a research note on Wednesday, November 28th. Finally, ValuEngine raised shares of Kura Oncology from a hold rating to a buy rating in a research note on Wednesday, November 7th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Kura Oncology presently has an average rating of Buy and a consensus target price of $28.17.
KURA stock opened at $16.76 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.76 and a current ratio of 14.76. The firm has a market capitalization of $626.47 million, a PE ratio of -11.03 and a beta of 3.16. Kura Oncology has a twelve month low of $10.20 and a twelve month high of $24.02.
In other news, major shareholder Ecor1 Capital Fund Qualified, purchased 40,538 shares of the business’s stock in a transaction on Thursday, December 13th. The shares were acquired at an average price of $13.90 per share, with a total value of $563,478.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.30% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers raised its holdings in Kura Oncology by 30.7% in the second quarter. Rhumbline Advisers now owns 23,647 shares of the company’s stock worth $430,000 after buying an additional 5,552 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Kura Oncology by 22.9% in the second quarter. Bank of New York Mellon Corp now owns 102,371 shares of the company’s stock worth $1,863,000 after buying an additional 19,072 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Kura Oncology by 26.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 57,135 shares of the company’s stock worth $1,040,000 after buying an additional 11,961 shares in the last quarter. Swiss National Bank purchased a new position in shares of Kura Oncology in the second quarter worth $768,000. Finally, BlackRock Inc. raised its stake in Kura Oncology by 25.5% during the second quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock valued at $36,440,000 after purchasing an additional 406,963 shares in the last quarter. 79.28% of the stock is owned by institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: How do taxes affect a CDs total return?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.